Medical Cannabis for Chronic Pain
ABSTRACT: There is mounting interest among patients and healthcare professionals about the clinical benefits of medical cannabis for various ailments, most commonly for pain relief. Some studies have concluded that medical cannabis may be an alternative for opioids in certain patient populations, while other studies concluded there is insufficient evidence. Medical cannabis is believed to be useful for treating several medical conditions and symptoms, and there is great debate about the safety and efficacy of cannabis for medicinal purposes. It is estimated that 2.1 million Americans use medical cannabis. The legalization and expansion of medical cannabis have created a great debate within the medical community. As the majority of states now allow medical cannabis use, pharmacists must be prepared to provide pharmaceutical care for patients who use medical cannabis, while practicing within the boundaries of the law.
According to a 2018 publication from the CDC, chronic pain has been cited as the most common reason adults in the United States seek medical care. 1 The reports states that in 2016, an estimated 20.4%—representing approximately 50 million U.S. adults—had chronic pain, and 8% had high-impact chronic pain that restricted or hindered at least one major life activity. 1 Chronic pain is common, expensive, and challenging to treat. Many individuals with chronic pain have turned to cannabis as an alternative form of pain management. 2 Moreover, interest in the use of cannabis and cannabinoids to treat chronic noncancer pain is escalating because of their potential to diminish opioid dose requirements. 3 For some, the augmented curiosity is due to their greater safety compared with opioids and the possibility that their use can decrease opioid dose requirements via an opioid-sparing effect. 3 Both factors have been proposed to contribute to fewer opioid-related deaths. 3
According to the National Institutes of Health’s National Center for Complementary and Integrative Health, medical marijuana, also known as cannabis, has been used in medical treatment for more than 3,000 years for a plethora of conditions, including pain relief, digestive issues, and psychological disorders. 4 While medical cannabis is thought to be useful for treating several medical conditions and symptoms, there is still great debate about the safety and efficacy of using cannabis for medicinal purposes. 5 Current U.S. medical usage is most commonly for pain, although it is also used for anorexia, nausea, glaucoma, and seizures. 5 In light of the ongoing opioid epidemic, many of those who suffer with chronic pain are looking for alternatives for analgesia. Results from a recent study revealed that more than 62% of individuals who use medical cannabis do so to treat chronic pain. 6 It is estimated that 2.1 million Americans use medical cannabis. 6 The World Health Organization reports that an estimated 2.5% of the global population uses cannabis annually, making it the most frequently used drug worldwide. 7 The discussion about medical cannabis continues for both prescribers and patients, and clearly, more research is warranted.
What Is Medical Cannabis?
For many patients and prescribers, there is increasing interest in the use of cannabis-based medicines, and researchers are exploring the benefits versus risks. 8 Cannabis-based medicines contain cannabinoids derived from the cannabis plant, including delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. 9 There is, however, ambiguity and disagreement regarding the use of cannabis-based medicines for the management of chronic pain. 9 The expanding interest about medical cannabis is believed to be related to growing concerns of addressing the ongoing opioid-abuse epidemic. 10 Some preliminary evidence suggests that patients who use cannabis may reduce their opioid use, but more research is needed. 11,12
Cannabis is made up of multiple types of phytocannabinoid components, the two most studied being THC and CBD. 13 In traditional cannabis sativa plants (sometimes called medical or recreational cannabis), THC and CBD are the two most abundant cannabinoid receptors. 13 To date, 568 unique molecules have been identified in cannabis; of these, more than 60 are cannabinoids—compounds that act on receptors in the body’s endocannabinoid system (ECS). 14 This system plays a key role in endogenous pain control. 14-17 Two of the cannabinoids found in cannabis, THC and CBD, along with other cannabinoids, terpenes, and flavonoid compounds, are thought to exhibit synergistic effects that promote pain relief. 16,17
THC is the most psychoactive cannabinoid found in cannabis and is principally responsible for the high associated with cannabis. 17 It can also diminish nausea and increase appetite. CBD does not provide the euphoria associated with THC and is associated with reduced pain and inflammation. 17 Two of the most commonly utilized cannabinoid receptors are CB1 (primarily in the brain and peripheral tissue) and CB2 (primarily in the immune and hematopoietic systems). 18 Because CBD acts on the CB2 receptors, it does not cause the significant psychoactive effects that THC does (THC acts primarily on the CB1 receptors). 19
State Legalization of Medical Cannabis
Despite the ever-expanding number of statutes approved by state legislatures, cannabis, whether used for medicinal or recreational purposes, remains illegal under federal law via the Controlled Substances Act. 20 As the majority of states now permit medical cannabis use, pharmacists must be prepared to provide pharmaceutical care for patients who use these therapies while practicing within the limits of the law. 20 Pharmacists should be aware of medical cannabis’ historical events, legislative timeline, legal considerations, professional dilemmas, and future implications so that they can effectively counsel patients about these issues. 20
The legalization and expansion of medical cannabis have created ongoing debate within the medical community, with input from the pharmacy profession being mostly left out of legislative discussions, and the construction of regulations linked to medical cannabis. 21 This is concerning given the variety of clinical issues that result from the use of medical cannabis, including an understanding of the disease states for which use is considered potentially beneficial. 21 Moreover, clinicians should consider that the possibility of drug-drug interactions is a significant concern that needs to be evaluated before patients begin using medical cannabis. 21
Due to their pharmacology expertise, pharmacists are an ideal asset to prescribers considering the use of medical cannabis for their patients since pharmacists can screen for potential contraindications and drug-drug interactions. Furthermore, pharmacists should become knowledgeable about the use of cannabis because some states require pharmacist involvement in the legal distribution of medical cannabis. 21 According to the American Association of Colleges of Pharmacy, many states, as well as the District of Columbia, Guam, and Puerto Rico, have legalized medical cannabis. 22 Three states are already requiring that pharmacists be part of the dispensing process, according to the National Community Pharmacists Association. 22 For example, New York State requires a pharmacist to be on the premises and supervising the activities within a cannabis-dispensing facility. 22
While medical cannabis presents many possibilities, the plant itself is extremely controversial, with questions over its legality, overall addictiveness, and effectiveness. 22 Surveys report that an estimated 85% of Americans support legalizing medical cannabis. 22 As of April 2019, medical cannabis was legal in 34 states, many of which necessitate patient registry or identification cards for the purchase and use of the substance for specific, diagnosed medical conditions. 16 These conditions differ by state and continue to change. At the federal level, marijuana is classified as a Schedule I substance under the Controlled Substances Act, and there are no recognized medical uses.
In many of the states with legalized cannabis, some type of product testing is required; however, testing varies by state and may be limited to contamination tests or may include quantification of CBD and THC levels. 16,23 California, for example, requires dispensaries to sell only cannabis that has been tested for pesticides, contaminants, and microbial impurities. 16,23 Starting in July 2018, California also began to require testing to ascertain plant potency (i.e., levels of THC and CBD). This information is included on the product label. 16,23 In addition, 12 states have enacted legislation allowing for limited use of medical cannabis (i.e., low CBD:THC ratios). These states, as of spring 2019, included Alabama, Georgia, Indiana, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Texas, Virginia, Wisconsin, and Wyoming. It is important to know that consistency and quality of the product received may differ from dispensary to dispensary and from state to state. 23
The majority of states with medical cannabis laws restrict its use to patients diagnosed with a predefined set of qualifying conditions, such as cancer, HIV/AIDS, multiple sclerosis, cachexia or wasting syndrome, glaucoma, amyotrophic lateral sclerosis, Crohn’s disease, and seizures. 24 More states are beginning to include pain, posttraumatic stress disorder, and problems with sleep. Some are less explicit—the District of Columbia and California both allow cannabis use for any condition that cannot be effectively treated by other means and that limits a patient’s ability to perform activities of daily living. 24
The evidence for cannabis’ treatment efficacy across different conditions fluctuates extensively, and comprehensive data on the conditions for which individuals use cannabis are deficient. 25 In a recent publication, Boehnke et al analyzed state-registry data to provide nationwide estimates characterizing the qualifying conditions for which patients are licensed to use cannabis medically. 25 They found that chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5% in 2016). 25 An estimated 85.5% of patient-reported qualifying conditions had either substantial or conclusive evidence of therapeutic efficacy. 25
Regulation of Cannabis and Cannabis-Derived Products
To date, the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition. 26 However, the FDA has approved one cannabis-derived and three cannabis-related drug products. 26 These approved products are only available with a prescription from a licensed healthcare provider. The FDA has approved Epidiolex, which contains a purified form of the drug substance CBD for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2 years and older. 26 The agency has also approved Marinol and Syndros for therapeutic uses in the U.S., including for the treatment of anorexia associated with weight loss in AIDS patients. 26 Marinol and Syndros include the active ingredient dronabinol, a synthetic THC, which is considered the psychoactive component of cannabis. 26 Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure comparable to THC and is synthetically derived. 26
Treating Chronic Pain
Cannabis has been employed to treat pain based on its action on both CB1 and CB2 receptors. 27 CB receptor agonists have been revealed to cause antinociceptive and antihyperalgesic effects by regulating neuronal and non–nervous system inflammatory activity. 27 One theory proposes that activation of CB1 receptors in mast cells elevates cyclic adenosine monophosphate and suppresses degranulation. 27 Analgesia may also result from CB1 receptor activation, causing negative modulation of the P2X3 receptor in primary afferent neurons. 28 Activation of CB2 receptors can hinder the release of proinflammatory factors, causing suppression of nerve growth factor–induced mast-cell degranulation and neutrophil accumulation. 27,28
A growing body of clinical research and a history of anecdotal evidence support the use of cannabis for the relief of some types of chronic pain, including neuropathic pain, and spasticity associated with multiple sclerosis. 14,29 In a recent comprehensive review of current data on the health effects of cannabis and cannabinoids, the National Academies of Sciences determined that adult patients with chronic pain who were treated with cannabis/cannabinoids were more likely to experience a clinically noteworthy reduction in pain symptoms. 29 They rated these effects as “modest.” 14,29 Studies also imply some efficacy for cancer-related pain, migraines, fibromyalgia, and other pain conditions. 14,30 It has been suggested that these compounds may be valuable in other conditions, including rheumatoid arthritis, osteoarthritis, and various other types of acute and chronic musculoskeletal pain. 31,32 However, how different cannabis species, routes of administration, and doses differ in their effect is less clear, and more research is required. 14
Chronic pain relief is by far the most common condition cited by patients using cannabis for medical purposes. Studies and observational reports have demonstrated that more than 80% of patients enrolled in clinical trials and/or with a medical cannabis card indicate “severe pain” as the reason for use. 29 In addition, evidence proposes that some individuals with chronic pain are substituting the use of opiates with cannabis. 29 Data from a survey directed by a Michigan medical cannabis dispensary claimed that use of medical cannabis was associated with a 64% decrease in use of opioids. 33 In addition, a recent analysis of prescription data from Medicare Part D enrollees in states with medical access to cannabis suggested a substantial reduction in prescriptions for conventional pain medications, principally opioids. 34
Clinical Study Results
A number of research studies examined the efficacy of medical cannabis on treating chronic pain and other conditions. For example, the findings from a 2019 study published in the Journal of Psychoactive Drugs, which evaluated data from 1,000 individuals taking legalized cannabis in one state, found that among the 65% of individuals taking cannabis for pain, 80% found it was very or tremendously helpful. 36 This led to 82% of these individuals being able to reduce, or halt, taking OTC pain medications and 88% being able to halt taking opioids. 35
In addition, results reported at the American Academy of Neurology 2019 Annual Meeting revealed that in a preliminary study, investigators at the Dent Neurologic Institute in Buffalo, New York, found that the cannabis provided elderly patients with relief from chronic pain, sleep disorders, and anxiety related to diseases such as amyotrophic lateral sclerosis, Parkinson disease, neuropathy, spinal cord damage, and multiple sclerosis. 6 Their findings show that medical cannabis is well tolerated in people aged 75 years and older and may improve symptoms such as chronic pain and anxiety. 6
Finally, some evidence suggests cannabinoids may diminish opioid requirements for analgesia, although this finding is not conclusive. 36 In a systematic review, Nielsen et al evaluated the effect of cannabinoids to reduce opioid requirements for analgesia and found some lower quality studies suggesting a reduction in opioid requirements during coadministration with cannabinoids. Higher quality studies, however, failed to confirm an opioid-sparing effect. 36
The Role of the Pharmacist
As the interest in using medical cannabis for pain relief continues, it is important that pharmacists are aware of the pros and cons of using medical cannabis. There is ongoing research about the ECS and the role of cannabinoid compounds in various medical conditions. As knowledge expands, it is critical that pharmacists are prepared to answer the questions and concerns of healthcare professionals and patients alike. While there are numerous areas of potential therapeutic development of products acting on the ECS intended to treat pain- and non–pain-related conditions, it is vital to recognize that the overall place in therapy for almost all of these products (pharmaceutical, botanical, or otherwise) is still widely unknown, and there is a growing need for more clinical safety and efficacy data since comprehensive information in these areas is still deficient. 13
Similarly, it is also crucial to consider that the majority of these products (especially those acting on CB1 and CB2 receptors) may be associated with cognitive dysfunction and increases in psychoactive behavior. It is imperative, therefore, that patients are advised to use these products with caution and to discuss their use with their primary healthcare provider. There is also a potential for drug-drug interactions (TABLE 1).
Clearly, the debate regarding the pros and cons associated with the use of medical cannabis will persist due to continuing legalization and research efforts. Therefore, it is imperative that pharmacists are knowledgeable about this issue and are prepared to answer clinician and patient questions. As one of the most accessible healthcare providers, pharmacists have a pivotal role in educating patients and prescribers about medical cannabis, including the current regulations and clinical studies exploring the potential uses of medical cannabis in chronic pain. There is ongoing research about the ECS and the role of cannabinoid compounds in various medical conditions. While various clinical studies have been conducted regarding the clinical benefits of medical cannabis, more research is required to better understand effective pain-management regimens for medical cannabis users.
What Are Medical Marijuana and Cannabidiol (CBD)? Everything You Need to Know
The cannabis plant, from which marijuana is derived, is often smoked for recreational purposes. But people are increasingly using marijuana to treat medical conditions — and this medical marijuana is not always smoked. It comes in many forms:
- Marijuana cigarettes containing the cannabinoids (chemical compounds) tetrahydrocannabinol (THC) or cannabidiol (CBD), or both THC and CBD
- CBD oils, edibles, tinctures, creams, and capsules
- Cannabis-derived pharmaceutical products approved by the Food and Drug Administration (FDA)
Studies suggest that the medical use of marijuana may help treat the following conditions or help alleviate the following symptoms: (1)
- Anxiety, particularly social anxiety disorder
- Chronic pain
Some research has suggested that the cannabinoids in marijuana could also be useful in managing these conditions: (2,3,4,5,6,7)
- HIV/AIDS like Crohn’s disease and irritable bowel syndrome (IBS)
According to a 2017 report from the National Academies of the Sciences, Medicine, and Engineering (NASME), the strongest scientific evidence so far has been found in support of using marijuana for chronic pain, cancer-related nausea and vomiting, and MS-related spasticity. (1)
This NASME report, one of the largest of its kind, looked at more than 10,000 studies published since 1999.
How Does Marijuana Affect the Body?
It depends on whether THC or CBD is the cannabinoid at work. They produce similar effects, but there are differences in intensity because they each affect a different neural pathway.
THC is thought to engage with the body’s endocannabinoid system, which helps regulate physiological functioning. THC is similar to a chemical that’s present in this system, and when these two chemicals meet, the similarity allows THC to exert an influence on the body and brain in ways that alter coordination, memory, decision-making, appetite, and mood.
The endocannabinoid system also helps regulate gastrointestinal functions, and this may explain why medical marijuana seems to help digestive disorders like IBS.
CBD, scientists think, affects the brain because of the way it interacts with the neurological pathways that regulate serotonin, the hormone that regulates anxiety, pain, nausea, and appetite.
How Marijuana Can Help Fight Chemotherapy-Induced Nausea
Medical Marijuana for Rheumatoid Arthritis Pain
Crohn’s and Medical Marijuana: What to Know About Symptoms and Treatment
Medical Marijuana May Ease Certain MS Symptoms
How Can Marijuana Help Opioid Use Disorder?
Some individuals use marijuana instead of addictive opioids to treat pain. In these cases, marijuana may actually be responsible for a decrease in the use of — and deaths from — these prescription drugs.
A study published in May 2018 in JAMA Internal Medicine reported that prescriptions for opioids decreased in states that have medical marijuana laws. Researchers looked at Medicare data from 2010 to 2015 and found that states with active dispensaries saw 3.742 million fewer daily doses of opioids filled by pharmacies. (8)
4 Doctors Comment on Legal Marijuana and Prescribing Fewer Opioids
Another study, published in October 2014 in JAMA Internal Medicine, found that states with medical cannabis laws had a 24.8 percent lower annual overdose rate than states without such laws. (9)
Some states, like Pennsylvania and New York, now consider opioid use disorder as a qualifying condition for medical marijuana use. New York, for example, allows people who qualify to use medical marijuana instead of opioids to treat pain.
What Is Cannabidiol and How Will It Affect Me?
Cannabidiol is the cannabinoid in marijuana that, along with interacting with the brain’s serotonin system, may also help relax and calm you, but it doesn’t alter your perception or affect physical reactions too much. CBD may be particularly effective for: (10)
- Anxiety disorders
- Nausea and vomiting
- Psychotic disorders
- Non-cancer-related pain
- Sleep problems (Dravet syndrome and Lennox-Gastaut syndrome)
Staci Gruber, MD , is an associate professor of psychiatry at Harvard Medical School in Boston and the director of the Marijuana Investigations for Neuroscientific Discovery program at McLean Hospital in Belmont, Massachusetts, which is researching the neurological effects of medical marijuana use.
In a large study that she’s conducting on the use of medical marijuana, Dr. Gruber says the second most commonly reported use of medical marijuana among subjects is for anxiety. She’s also about to begin an FDA-approved clinical trial of a CBD sublingual (administered under the tongue) tincture, consisting of CBD in a coconut oil base, for the treatment of anxiety. (Tinctures are medicines — in this case CBD — dissolved in a liquid like alcohol or glycerine.)
Indeed, anecdotal evidence points to the effectiveness of CBD as an anxiety and stress reducer, as well as a sleep aid. Eric*, a busy sales executive in San Francisco, has been sleeping more soundly since he started using a high-CBD, low-THC product via a vaporizer three months ago for work-related stress and anxiety.
“The quality of my sleep is better, I’m sleeping longer and deeper, and I now have no problem falling and staying asleep,” he says. “It has changed my life.”
In addition to being a potentially powerful treatment for anxiety disorders, a growing body of research is suggesting that CBD may help treat symptoms of neurological disorders such as Parkinson’s disease and Alzheimer’s disease . (11,12)
Scientists think that CBD acts in yet to be determined ways that protect the brain against inflammation and oxidative stress. (13)
Research also points to CBD as a potential treatment for psychosis and schizophrenia . (14,15)
Medical marijuana may also be effective in palliative care. In one Canadian case study, published in 2013 in Case Reports in Oncology, physicians reported that CBD oil, administered orally, was a successful treatment for a 14-year-old patient in palliative care with an aggressive form of leukemia. (16)